One Lambda, Inc.

Xoma Corporation

International Genetic Engineering

Emory University

One Lambada

Zoma Corporation

Jar-how Lee

Lindley C. Blair

Raju K. Koduri

Joachim L. Weickmann

Jar-How Lee

Rui Pei

Lindley Blair

Jiunu S Lai

Thoa Nong

Katsuyuki Saito

Gary L Wilcox

Dan S Ray

Neng Jen Remi Shih

Yun-Long Lin

James E Callaway

Raju K Koduri

Julie Nguyen

Terrence Chen

Arnold H Horwitz

Joachim L Weickmann

Stewart Han

Thao Nong

Robert A Bray

Lindley C Blair

Described herein are materials and methods of incorporating CLIP peptide into the peptide binding groove of HLA Class II antigens and using such HLA Class II antigens for the detection of alloantibodies.

Methods of detecting alloantibodies to HLA class II antigens

Described herein are materials and methods for detecting alloantibodies using both HLA and non-HLA antigens in a single assay.

Methods of detecting alloantibodies using HLA and non-HLA antigens

A method providing next generation sequencing (NGS)-based high-resolution HLA typing as a routine clinical test. The method uses a multiplex PCR primer design for amplifying multiple human leukocyte antigen (HLA) Class I and Class II genes in a single reaction for NGS. The test quality is improved and the protocol for typing multiple HLA genes is simplified because the number of amplification reactions are reduced nearly 10-fold, to yield a substantially equimolar ratio of individual HLA gene amplification products. The invention eliminates an amplicon pooling step, reducing the reagent cost, and required sample DNA quantity.

Single reaction multiplex PCR primer design for amplifying multiple HLA class I and II genes

The invention is directed to engineered Fc gamma receptor type III (Fc&#x3b3;II, HNA-1) polypeptides and use of these polypeptides to detect antibodies specific for human neutrophil antigens (HNA). The invention is also directed to methods for the diagnosing and determining susceptibility for developing Transfusion Reaction Acute Lung (TRALI).

Modified Fc gamma receptor type III (FcgammaIII, HNA-1) polypeptides and the uses thereof

The invention is directed to engineered Fc gamma receptor type III (Fc&#x3b3;111, HNA-1) polypeptides and use of these polypeptides to detect antibodies specific for human neutrophil antigens (HNA). The invention is also directed to methods for the diagnosing and determining susceptibility for developing Transfusion Reaction Acute Lung (TRALI).

Modified Fc gamma receptor type III (FC&#x3b3;III, HNA-1) polypeptides and the uses thereof

The invention provides methods for detecting target nucleic acid sequences with diagnostic probes including first and second probe regions that are substantially complementary to first and second target regions respectively on a target nucleic acid strand wherein the first probe region is located 5' to the second probe region. The first probe region is substantially complementary to the first target region, on the target nucleic acid strand, which also includes a second target region, wherein when the first target region is contiguous with the second target region on the target nucleic acid strand, then the first and second probe regions on the diagnostic probe are separated by a spacer region of nucleic acid.

Diagnostic probe detection system

The present invention relates to a kit for conducting a method of measuring binding interactions using multiple sets of microparticles, wherein said set has the same identifiable characteristic and wherein one of more sets comprise subsets of microparticles and said subset presents at least one unique probe that acts as a binding partner for a target molecule in a biological sample. In particular, the invention provides for a kit for conducting a method of DNA-based tissue-typing antigens in donor tissue or recipient tissue using these multiple sets of microparticles.

Methods of screening for binding interaction using sets of microparticles and unique probes

The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for methods of removing antibodies specific for denatured HLA antigens or antibodies specific for native HLA antigens from a serum sample. In addition, the invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ.

Methods of detecting antibodies specific for denatured HLA antigens

The present invention relates to methods for screening for binding interactions using multiple sets of microparticles, wherein said set has the same identifiable characteristic and wherein one of more sets comprise subsets of microparticles and said subset presents at least one unique probe that acts as a binding partner for a target molecule in a biological sample. In particular, the invention provides for methods of detecting tissue-typing antigens in donor tissue or recipient tissue using these multiple sets of microparticles.

Method of screening for binding interaction using sets of microparticles and unique probes

The invention provides methods for detecting target nucleic acid sequences with diagnostic probes including first and second probe regions that are substantially complementary to first and second target regions respectively on a target nucleic acid strand wherein the first probe region is located 5' to the second probe region. The first probe region is substantially complementary to the first target region, on the target nucleic acid strand, which also includes a second target region, wherein when said first target region is contiguous with the second target region on the target nucleic acid strand, then the first and second probe regions on the diagnostic probe are separated by a spacer region of nucleic acid.

The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ.

The present invention provides an improved method for detection of panel reactive antibodies in serum of a subject against HLA class I antigens, which comprises the steps of adding serum from a subject to an array of microbeads, each microbead presenting HLA antigens from a cell population presenting the same HLA antigens; incubating the serum and microbeads for sufficient time for anti-HLA antibodies in the serum to bind to the HLA antigens presented on the microbeads; removing the serum components which do not specifically bind with the HLA antigens presented on the microbeads; incubating the microbeads with a labeled ligand capable of specifically binding with anti-HLA antibodies bound to said HLA antigens; removing the labeled ligand which is not bound to said HLA antigens; and detecting the presence of labeled ligand bound to said HLA antigens by flow cytometry.

Method for immunobead flow cytometric detection of anti-HLA panel reactive antibody

The invention provides methods for detecting target nucleic acid sequences with diagnostic primers including priming regions and probe regions which are complementary to target and reference regions respectively on a sample nucleic acid strand wherein the probe region is located 5&prime; to the priming region which is complementary to a reference nucleic acid sequence which is 3&prime; to the target nucleic acid sequence on the sample nucleic acid strand wherein when said reference nucleic acid sequence is contiguous with said target nucleic acid sequence on the sample nucleic acid strand then the priming region and probe region on the diagnostic probe are separated by a spacer region of nucleic acid.

Method for amplification of DNA

The present invention provides a kit for the improved method for detection of panel-reactive antibodies in serum of a subject against HLA Class I antigens, which comprises an array of microbeads, each microbead presenting HLA antigens from a cell population presenting the same HLA antigens. In the method, serum from a subject is added to said array of microbeads then the mixture is incubated for a sufficient time for anti-HLA antibodies in the serum to bind to the HLA antigens presented on the microbeads. After removing serum components which do not specifically bind with the HLA antigens presented on said microbeads, the microbeads are incubated with a labeled ligand capable of specifically binding with anti-HLA antibodies bound to said HLA antigens. The labeled ligand which is not bound to said HLA antigens are removed and the presence of labeled ligand bound to said HLA antigens are detected by flow cytometry.

Growing community of inventors

Los Angeles, CA, United States of America

Jar-How Lee